ATE485058T1 - Zusammensetzung enthaltend eine kombination aus einem ppar-alpha, pravastatin und polyglykolisiertem glyzerid - Google Patents

Zusammensetzung enthaltend eine kombination aus einem ppar-alpha, pravastatin und polyglykolisiertem glyzerid

Info

Publication number
ATE485058T1
ATE485058T1 AT02766983T AT02766983T ATE485058T1 AT E485058 T1 ATE485058 T1 AT E485058T1 AT 02766983 T AT02766983 T AT 02766983T AT 02766983 T AT02766983 T AT 02766983T AT E485058 T1 ATE485058 T1 AT E485058T1
Authority
AT
Austria
Prior art keywords
pravastatin
ppar
alpha
combination
composition containing
Prior art date
Application number
AT02766983T
Other languages
English (en)
Inventor
Francis Vanderbist
Arthur Deboeck
Philippe Baudier
Antonio Sereno
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar M F filed Critical Galephar M F
Priority claimed from PCT/BE2002/000135 external-priority patent/WO2003013608A1/en
Application granted granted Critical
Publication of ATE485058T1 publication Critical patent/ATE485058T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02766983T 2001-08-07 2002-08-07 Zusammensetzung enthaltend eine kombination aus einem ppar-alpha, pravastatin und polyglykolisiertem glyzerid ATE485058T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE0100133 2001-08-07
PCT/BE2001/000147 WO2003013607A1 (en) 2001-08-07 2001-09-07 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
PCT/BE2002/000135 WO2003013608A1 (en) 2001-08-07 2002-08-07 ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR

Publications (1)

Publication Number Publication Date
ATE485058T1 true ATE485058T1 (de) 2010-11-15

Family

ID=3862570

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02748487T ATE322896T1 (de) 2001-08-07 2002-07-17 Verbesserte pharmazeutische zusammensetzung mit einem ppar-alpha-mittel und verfahren zu ihrer herstellung
AT02766983T ATE485058T1 (de) 2001-08-07 2002-08-07 Zusammensetzung enthaltend eine kombination aus einem ppar-alpha, pravastatin und polyglykolisiertem glyzerid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02748487T ATE322896T1 (de) 2001-08-07 2002-07-17 Verbesserte pharmazeutische zusammensetzung mit einem ppar-alpha-mittel und verfahren zu ihrer herstellung

Country Status (7)

Country Link
US (2) US20070092567A1 (de)
AT (2) ATE322896T1 (de)
DE (1) DE60238059D1 (de)
DK (1) DK1414496T3 (de)
ES (1) ES2352189T3 (de)
PT (1) PT1414496E (de)
WO (2) WO2003013607A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534660A1 (en) * 2003-08-05 2005-02-10 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
WO2005013940A1 (en) * 2003-08-06 2005-02-17 Galephar M/F Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
CN103040798A (zh) * 2011-11-08 2013-04-17 深圳信立泰药业股份有限公司 一种苯扎贝特缓释药物组合物
CN110496108A (zh) * 2011-12-14 2019-11-26 Lts勒曼治疗系统股份公司 用于非诺贝特的具有提高的溶出度的糯米纸囊制剂和胶囊制剂
KR102501636B1 (ko) * 2021-12-07 2023-02-21 에이스바이오팜 주식회사 페노피브린산을 포함하는 경구용 정제 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
HRP20020950A2 (en) * 2000-06-09 2004-12-31 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6534088B2 (en) * 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
WO2003013501A1 (en) 2003-02-20
US20150037414A1 (en) 2015-02-05
ATE322896T1 (de) 2006-04-15
PT1414496E (pt) 2012-04-20
WO2003013607A1 (en) 2003-02-20
DE60238059D1 (de) 2010-12-02
DK1414496T3 (da) 2011-01-24
US20070092567A1 (en) 2007-04-26
ES2352189T3 (es) 2011-02-16

Similar Documents

Publication Publication Date Title
DE60127457D1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
ATE129894T1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
ATE147592T1 (de) Vitamine und mineralien enthaltende nahrungszusätze
MX173727B (es) Composicion farmaceutica oral con baja dosifica cion de inhibidor de plaquetas/anticoagulante
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
JPS57145803A (en) External decoloring agent for skin
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
ATE317280T1 (de) Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
ATE258792T1 (de) Diät mit hohem lipidgehalt
ATE138639T1 (de) L-carnitin- und alkanoyl-l-carnitin-ester mit glykolsäure oder ihre ester und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von dermatosen
DE69922496D1 (de) Nahrungsmittel enthaltend eine mesomorphe phase aus monoglyceriden
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
NZ522242A (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
SI1651194T1 (sl) Stabilni farmacevtski sestavki za nadzorovano sproščanje, ki vsebujejo fenofibrat in pravastatin
DE60238059D1 (de) Zusammensetzung enthaltend eine kombination aus einem ppar-alpha, pravastatin und polyglykolisiertem glyzerid
DK0667155T3 (da) Tabletter med thioctsyre med bestemt kornstørrelse
ATE258435T1 (de) Pinolensäure gegen diabetes
NO932843D0 (no) Farmasoeytiske preparater
RU93042903A (ru) Биологически активная добавка к пище "женьшень медовый"
DE69423623D1 (de) Aminosäureergänzung
ZA866510B (en) Esters of cyclopropane carboxylic acid and of 2,3-dihydro-4-phenyl-1h-inden-2-ol,their preparation,their use in the fight against parasites and the compositions containing them
RU94008707A (ru) Готовые формы для снижения болезнетворного воздействия курения и способ применения их

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414496

Country of ref document: EP